Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia

A. Janssens, F. Rodeghiero, D. Anderson, BH. Chong, Z. Boda, I. Pabinger, L. Červinek, DR. Terrell, X. Wang, J. Franklin,

. 2016 ; 95 (7) : 1077-87. [pub] 20160430

Language English Country Germany

Document type Clinical Trial, Phase IV, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc17013900

The effects of romiplostim on bone marrow morphology were evaluated in adults with immune thrombocytopenia (ITP). Patients with platelet counts <50 × 10(9)/L, ≥1 prior ITP therapies, and no collagen at baseline received weekly subcutaneous romiplostim starting at 1 μg/kg, adjusted to maintain platelet counts between 50 and 200 × 10(9)/L. Biopsies were scheduled after 1, 2, or 3 years of romiplostim (cohorts 1, 2, and 3, respectively). Irrespective of scheduled time, biopsies were performed earlier if patients discontinued or failed to achieve/maintain a response to romiplostim. Reticulin (silver stain) and collagen (trichrome stain) were graded by two hematopathologists using the modified Bauermeister scale (0-4). Of 169 patients, 131 had evaluable biopsies; 9/131 (6.9 %) had increases of ≥2 grades on the modified Bauermeister scale (cohort 1: 0/34; cohort 2: 2/39; cohort 3: 7/58), including two with collagen. Three of the nine patients had follow-up biopsies, including one patient with collagen; changes were reversible after romiplostim discontinuation. Of the nine patients, one had neutropenia detected by laboratory test and two had adverse events of anemia, both non-serious and not treatment-related. By actual exposure (as some biopsies did not occur as scheduled), the number of patients with grade increases ≥2 were year 1: 3/41, year 2: 1/38, year 3: 5/52. Twenty-four patients sustained platelet counts ≥50 × 10(9)/L for ≥6 months with no ITP medications after discontinuing romiplostim, i.e., they entered clinical remission of their ITP. In conclusion, in patients with ITP receiving romiplostim, bone marrow changes were observed in a small proportion of patients.ClinicalTrials.gov identifier: NCT#00907478.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013900
003      
CZ-PrNML
005      
20170425122518.0
007      
ta
008      
170413s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-016-2682-2 $2 doi
035    __
$a (PubMed)27130310
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Janssens, Ann $u Department of Hematology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium. ann.janssens@uzleuven.be.
245    10
$a Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia / $c A. Janssens, F. Rodeghiero, D. Anderson, BH. Chong, Z. Boda, I. Pabinger, L. Červinek, DR. Terrell, X. Wang, J. Franklin,
520    9_
$a The effects of romiplostim on bone marrow morphology were evaluated in adults with immune thrombocytopenia (ITP). Patients with platelet counts <50 × 10(9)/L, ≥1 prior ITP therapies, and no collagen at baseline received weekly subcutaneous romiplostim starting at 1 μg/kg, adjusted to maintain platelet counts between 50 and 200 × 10(9)/L. Biopsies were scheduled after 1, 2, or 3 years of romiplostim (cohorts 1, 2, and 3, respectively). Irrespective of scheduled time, biopsies were performed earlier if patients discontinued or failed to achieve/maintain a response to romiplostim. Reticulin (silver stain) and collagen (trichrome stain) were graded by two hematopathologists using the modified Bauermeister scale (0-4). Of 169 patients, 131 had evaluable biopsies; 9/131 (6.9 %) had increases of ≥2 grades on the modified Bauermeister scale (cohort 1: 0/34; cohort 2: 2/39; cohort 3: 7/58), including two with collagen. Three of the nine patients had follow-up biopsies, including one patient with collagen; changes were reversible after romiplostim discontinuation. Of the nine patients, one had neutropenia detected by laboratory test and two had adverse events of anemia, both non-serious and not treatment-related. By actual exposure (as some biopsies did not occur as scheduled), the number of patients with grade increases ≥2 were year 1: 3/41, year 2: 1/38, year 3: 5/52. Twenty-four patients sustained platelet counts ≥50 × 10(9)/L for ≥6 months with no ITP medications after discontinuing romiplostim, i.e., they entered clinical remission of their ITP. In conclusion, in patients with ITP receiving romiplostim, bone marrow changes were observed in a small proportion of patients.ClinicalTrials.gov identifier: NCT#00907478.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kostní dřeň $x účinky léků $x metabolismus $x patologie $7 D001853
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolagen $x metabolismus $7 D003094
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a počet trombocytů $x metody $7 D010976
650    _2
$a prospektivní studie $7 D011446
650    _2
$a idiopatická trombocytopenická purpura $x farmakoterapie $x metabolismus $x patologie $7 D016553
650    _2
$a receptory Fc $x terapeutické užití $7 D011961
650    _2
$a rekombinantní fúzní proteiny $x škodlivé účinky $x terapeutické užití $7 D011993
650    _2
$a retikulin $x metabolismus $7 D012155
650    _2
$a thrombopoetin $x škodlivé účinky $x terapeutické užití $7 D013926
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Rodeghiero, Francesco $u Department of Cell Therapy and Hematology, San Bortolo Hospital, Viale Rodolfi, 37, 36100, Vicenza, Italy.
700    1_
$a Anderson, David $u Dalhousie University, QEII-Bethune Building, Suite 442 Bethune Building, 1276 South Park Street, Halifax, NS, B3H 2Y9, Canada. $7 gn_A_00006113
700    1_
$a Chong, Beng H $u St. George Hospital, UNSW Medicine, UNSW, Sydney, 2052, Australia.
700    1_
$a Boda, Zoltán $u Clinical Center Department of Medicine, Thrombosis Haemostasis Center, University of Debrecen, H-4012 Debrecen, Nagyerdei krt. 98. POB.: 20, Debrecen, Hungary.
700    1_
$a Pabinger, Ingrid $u Medizinische Universitaet Wien, Universitaetsklinik fuer Innere Medizin I Waehringer Guertel 18-20, A-1090, Vienna, Austria.
700    1_
$a Červinek, Libor $u University Hospital Masaryk University, Jihlavská 340/20, 625 00, Brno, Czech Republic.
700    1_
$a Terrell, Deirdra R $u Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, 801 NE 13th, CHB 333, Oklahoma City, OK, 73104, USA.
700    1_
$a Wang, Xuena $u Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
700    1_
$a Franklin, Janet $u Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 95, č. 7 (2016), s. 1077-87
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27130310 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170425122835 $b ABA008
999    __
$a ok $b bmc $g 1200365 $s 974678
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 95 $c 7 $d 1077-87 $e 20160430 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Archiving options